Loading...
Docoh

SAB Biotherapeutics (SABS)

News

From Benzinga Pro
Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $7
13 May 22
News, Price Target, Analyst Ratings
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $10 to $7.
SAB Biotherapeutics Q1 EPS $0.02 Down From $0.05 YoY
12 May 22
Earnings, News
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly earnings of $0.02 per share. This is a 60 percent decrease over earnings of $0.05 per share from the same period last year.
51 Biggest Movers From Yesterday
6 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 Apr 22
Intraday Update, Markets, Movers
30 Stocks Moving In Tuesday's Mid-Day Session
5 Apr 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 139% to $5.40 after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $10
1 Apr 22
News, Price Target, Analyst Ratings
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $17 to $10.
53 Biggest Movers From Yesterday
1 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Thursday's Intraday Session
31 Mar 22
Intraday Update, Movers
36 Stocks Moving In Thursday's Mid-Day Session
31 Mar 22
News, Intraday Update, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Thursday's After-Market Session
24 Mar 22
Movers
Gainers
Stocks That Hit 52-Week Lows On Tuesday
8 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday's session saw 729 companies set new 52-week lows.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
6 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
68 Biggest Movers From Yesterday
3 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
Mid-Afternoon Market Update: Dow Gains 2%; SAB Biotherapeutics Shares Slide
2 Mar 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 2% on Wednesday.
12 Health Care Stocks Moving In Wednesday's Intraday Session
2 Mar 22
Intraday Update, Markets, Movers
41 Stocks Moving In Wednesday's Mid-Day Session
2 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.
Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels
2 Mar 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday.
Stocks That Hit 52-Week Lows On Wednesday
2 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 107 companies set new 52-week lows.
Mid-Morning Market Update: U.S. Stocks Mixed; Dollar Tree Reports Mixed Q4 Results
2 Mar 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks opened mixed this morning, with the Dow Jones adding more than 200 points on Wednesday.
NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185
2 Mar 22
Biotech, News, Penny Stocks, Health Care, General

Press releases

From Benzinga Pro
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
12 May 22
Earnings, Press Releases
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
12 May 22
News, Press Releases
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May 23-26, 2022. As part
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
29 Mar 22
Earnings, Press Releases
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
1 Mar 22
Health Care, Press Releases
In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
25 Feb 22
Press Releases, General
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (NASDAQ:SABS), a clinical-stage